Edition:
United States

Synthetic Biologics Inc (SYN.A)

SYN.A on American Stock Exchange

0.65USD
22 Nov 2017
Change (% chg)

$0.02 (+3.66%)
Prev Close
$0.63
Open
$0.60
Day's High
$0.68
Day's Low
$0.55
Volume
206,938
Avg. Vol
97,156
52-wk High
$1.05
52-wk Low
$0.41

Chart for

About

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $80.79
Shares Outstanding(Mil.): 128.57
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.71 15.46
EPS (TTM): -- -- --
ROI: -- -10.20 11.85
ROE: -- -36.19 15.83

BRIEF-Synthetic Biologics reports Q3 2017 ‍net loss per share of $0.14

* Synthetic Biologics reports third quarter 2017 operational highlights and financial results

Nov 01 2017

BRIEF-Synthetic Biologics reports qtrly loss per share $‍0.03​

* Synthetic Biologics reports second quarter 2017 operational highlights and financial results

Aug 03 2017

BRIEF-Synthetic Biologics announces allowance of U.S. Patent covering Syn-010

* Synthetic Biologics announces allowance of key U.S. Patent covering Syn-010 intended for the novel treatment of irritable bowel syndrome with constipation (IBS-C)

Jun 27 2017

Earnings vs. Estimates